http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-46462-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a717ea5b2ac78ac329ab3a9659d834d2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-6555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103 |
| filingDate | 1978-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1983-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-46462-B1 |
| titleOfInvention | Somatostatin peptide analogues |
| abstract | Peptide derivs. of somatostatin of formula (I) and their pharmaceutically tolerable salts are new: X-Cys-X1-X2-Phe-Phe-X3-Lys-Thr-Phe-Thr-Ser-X4-OH X = H or the two gps. A form a direct bond between the S-atoms in the molecule to give a cyclic structure, or each A represents a direct bond to an S-atom of a further cpd. (I) to form a linear or cyclic polymeric structure with 2-100 structural units of formula (I) (the terminal S-atoms in a linear polymeric structure being satd. with H); X = H, Ala-Gly, Gly-Gly, Ala-D-Ala, Gly-Gly-Gly, acetyl or benzoyl; X1 = His or Arg; X2 is His, Glu or Asp; X3 is Trp, D-Trp or 6-F-D-Trp; and X4 is Cye or D-Cys. Also new and claimed are intermediates of formula (I) which are converted to (I) by deprotection. R1-Cys-B1-B2-Phe-Phe-X3-Lys-Thr-Phe-Thr-Ser-X4-OR where B1 and B2 are carboxy-protected X1 and X2, and all the R gps. are protecting gps. (I) inhibit the release of somatotropin, glucagon and/or insulin. By controlling the dosage they can be used to inhibit somatotropin and glucagon release without affecting endogenous insulin levels. (I) are useful in the treatment of acromegaly, juvenile diabetes and diabetes mellitus. For treatment of diabetes mellitus, they can also be used in combination with insulin. Specific peptides (I) includes L-cysteinyl-L-histidyl-L-histidyl-L-phenylalanyl-D-tryptophyl-L-l- ysyl-L-threonyl -L-phenylalanyl-L-threonyl-L-seryl-L-cysteinyl cyclic (1-12)disulphide. |
| priorityDate | 1977-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.